Liquidia Corporation Share Price
NASDAQ: LQDA | Mid CapLiquidia Corporation Stock Performance
Open $90.39 | Prev. Close $89.31 | Circuit Range N/A |
Day Range $88.80 - $91.06 | Year Range $19.16 - $91.28 | Volume 22,658 |
Average Traded $89.99 |
Liquidia Corporation Share Price Today
As of 10 August 2026, Liquidia Corporation's share price is $90.18. The stock opened at $90.39, compared to its previous close of $89.31. During today's trading session, Liquidia Corporation's share price traded between $88.80 and $91.06, with an average price of $89.93. Over the past 52 weeks, the stock has recorded a high of $91.28 and a low of $19.16. In terms of performance, Liquidia Corporation's share price has risen by 190.72% over the last six months and is up 225.79% on a year-on-year basis.
Liquidia Corporation Share Price Chart
Liquidia Corporation Stock Fundamentals & Key Indicators
Market Cap $7.76B | PE Ratio (TTM) -112.73 | Dividend Yield N/A |
EPS (TTM) $-0.80 | Revenue (TTM) $158.32M | Return On Equity (TTM) -154.03% |
Profit Margin -43.53% | Debt to Equity 3.03 | Quarterly Earnings Growth YoY 84.74% |
Liquidia Corporation Quarterly Profit & Loss
All figures in USD
Liquidia Corporation Annual Profit & Loss
All figures in USD
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia Corporation Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $80.70 | $90.23 | +7.31% |
Jul 2026 | $78.77 | $84.09 | +5.43% |
Jun 2026 | $60.30 | $79.76 | +28.95% |
May 2026 | $38.95 | $61.85 | +57.67% |
Apr 2026 | $37.91 | $39.23 | +4.03% |
Mar 2026 | $30.72 | $37.71 | +21.57% |
Feb 2026 | $43.17 | $31.02 | -26.87% |
Jan 2026 | $34.66 | $42.42 | +22.89% |
Dec 2025 | $32.13 | $34.52 | +5.81% |
Nov 2025 | $27.04 | $32.63 | +33.93% |
Oct 2025 | $22.32 | $24.36 | +7.12% |
Sep 2025 | $27.99 | $22.74 | -17.85% |
LQDA Share Price FAQs
What is Liquidia Corporation share price today?
What is the 52 week high and 52 week low of Liquidia Corporation stock?
What is LQDA's market capitalisation today?
What is LQDA's net income for the last quarter?
What is the 5 year returns of LQDA?
What is the high & low stock price of LQDA today?
Can I buy LQDA shares in India?